Skip to main content
. 2014 Aug 4;9(8):e104040. doi: 10.1371/journal.pone.0104040

Figure 6. Olmesartan downregulates CARP and ameliorates cardiomyocyte hypertrophy.

Figure 6

(A) Treatment with RNH6270 (RNH 1 µM, active form of olmesartan) reduced Ang II (1 µM) -induced increased of CARP protein in NRVCs (*P<0.05 vs. control, #P<0.05 vs. Ang II. n = 3). (B) ANP mRNA expression in NRVCs exposed to Ang II (1 µM) stimulation in the presence/absence of RNH (1 µM). (C) Representative picture of whole heart from different group (scale bar = 2 mm). (D) HW/BW ratio was significantly lower in TAC mice treated with olmesartan medoxomil (OM) in comparison with untreated TAC mice, while addition of Ad-Ankrd1 partially blocked the antihypertrophic effect of OM. (*P<0.01 vs. Sham, #P<0.01 vs. TAC, &P<0.05 vs. TAC + OM, n = 4–6 in each group). (E) Olmesartan treatment for 4 weeks reduced the myocardial expression of CARP in TAC mice (*P<0.05 vs. Sham, #P<0.05 vs. TAC). Data are mean ± SEM.